Author: Marie Jones

  • From Red Gold to Olympic Gold: Seedo Corp. Seeks Solutions for Athletes and More

    From Red Gold to Olympic Gold: Seedo Corp. Seeks Solutions for Athletes and More

    Seedo Corp. (http://saffron-tech.ag) (OTC: SEDO), an agtech company that is developing the protocols to grow saffron using vertical farming technology, today announced that it is expanding its research to include the study of the spice’s well known natural anti-anxiety and antidepressant properties. Similar to the approach of the indoor cannabis industry, Seedo hopes to be able to enhance the medicinal properties of this unique herb for use in pharmaceutical and nutraceutical applications. Mental health has come to the forefront in sports with Simone Biles withdrawing from the Tokyo Olympics and Naomi Osaka opting out of the French Open and Wimbledon. With mental health entering the cultural conversation, Seedo Corp. hopes saffron will be seen as part of a new nature-based approach to mental health.

    Simone Biles

    “The timing is right to leverage saffron’s potential medicinal properties and create new applications that could address the recent paradigm shift regarding mental health,” says David Freidenberg, CEO. “Seedo Corp is committed to developing breakthroughs rooted in nature that are effective and safe for athletes and everyday consumers alike.”

    “Until recently, the options for treating depression and anxiety were quite limited,” says Dr. Nizan Primor, CEO, Naveh Pharma, a company that specializes in creating pharmaceutical and healthcare products with unique active ingredients including saffron. “A recent study (https://pubmed.ncbi.nlm.nih.gov/31118846/) found that taking 28 mg of saffron daily was just as effective as Fluoxetine, Imipramine, and Citalopram — conventional treatments for depression.”

    A fascinating study was published in the Journal of Adolescent Psychopharmacology (https://pubmed.ncbi.nlm.nih.gov/30741567/) which explicitly found that saffron extract has the same efficacy as Ritalin in improving focus for children with ADHD, suggesting there is a promising future in developing new natural therapies to treat these common ailments. In another recent study by the Journal of Psychopharmacology (https://journals.sagepub.com/doi/abs/10.1177/0269881119867703) it was discovered that patients who were administered saffron extract for eight weeks saw “a greater improvement in depressive symptoms.”

    Seedo Corp successfully harvests saffron using vertical farming technology. Seedo Corp hopes to expand the billion dollar saffron market by producing a reliable, consistent and large-scale supply of the spice.

    About Seedo

    Seedo Corp. (OTC: SEDO) is an agtech company that focuses on the research, development, and commercialization of agriculture products that are high in demand but are hindered by the low yields and specifications required by traditional farming. Seedo’s technology is aimed at offering a responsible and sustainable way to grow crops in a world confronted by environmental challenges and dwindling earth reserves, diminishing water sources and unstable weather conditions.

    Cautionary Note Regarding Forward-Looking Statements

    This letter contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to our ability to successfully execute a smooth transition of CFO functions as well as our ability to retain and recruit qualified executives; uncertainties related to, and failure to achieve, the potential benefits and success of our senior management team and organizational structure; our ability to successfully compete in the marketplace; our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in our Quarterly Reports on Form 10-Q and in our Annual Report on Form 10-K, including in the sections captioned “Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

    Contact:
    David Freidenberg,
    Chief Executive Officer
    info@saffron.ag
    +1 (800) 608-6432

  • Spritzer Malaysia Offers Exclusive Promotions to Quench Thirst on Hot Days

    • Shoppers can get attractive vouchers, half-off prices and free shipping from Spritzer’s Shopee store

    Spritzer Malaysia (Spritzer or the Company), which produces Malaysia’s best-selling natural mineral water, is having exclusive promotions on the Company’s official Shopee store in conjunction with Shopee’s 8.8 Brands Festival that ends on 08 August 2021.

    Stay safe, remain hydrated and healthy in this hot weather by shopping for various Spritzer Natural Mineral Water subscription plans from the comfort of home through https://shopee.com.my/spritzer.os from as low as RM127.50 per month catering to different household needs that can be delivered safely to your doorsteps.

    In addition, every subscription plan comes with a trendy rechargeable water pump dispenser that is not only functional but also lightweight in design, compact and portable.

    Spritzer is also pleased to introduce So Tinge!, a new line of fruit flavoured carbonated drinks coming in three flavours – watermelon, grape and lemon packed in 325ml bottles that is refreshing and thirst quenching on a hot day.

    In conjunction with Shopee’s 8.8 Brands Festival, Spritzer is offering on the Company’s official Shopee store the Spritzer Sparkling range at 50% off the regular price. Up until 08 August 2021, consumers can also enjoy the following attractive store vouchers:
    – RM10 off, with a minimum spend of RM120
    – 88% off, with a minimum spend of RM1, capped at RM5
    – 50% off, with a minimum spend of RM1, capped at RM5

    Besides these attractive offers, consumers who shop on the Spritzer official Shopee store can get free shipping with a lowered minimum spend of RM8, daily 88% off and RM8 branded deals. There are also up to 38 million Shopee Coins up for grabs with Shopee prizes when shoppers play Shopee Farm, Spin & Win, Shopee Bubble, Shopee Candy and more.

    Check out Spritzer’s official Shopee store to find out more – https://shopee.com.my/spritzer.os.

    Contact:
    Muhammad Hakim
    Email: h.juraimi@swanconsultancy.biz

    About Spritzer Berhad
    Spritzer Berhad (MY:7103; SPZ.MY; SPTZ.KL) is the largest bottled water producer in Malaysia. The brand, SPRITZER, is Malaysia’s best selling natural mineral water, produced and bottled from a vast environmentally-friendly 220 acre site replete with plentiful natural mineral water resources and lush greenery. Learn more at http://www.spritzer.com.my.

  • ClinTex (CTi) Launches CTi-OEM Blockchain Clinical Trial App

    ClinTex (CTi) Launches CTi-OEM Blockchain Clinical Trial App

    The ClinTex (CTi) tokenized platform (clintex.io) will be the first of its kind to utilize blockchain-based clinical data analytics to address the main causes of clinical trial inefficiency, helping to drive down the cost of new medicines and expediting their delivery to patients.

    ClinTex (CTi) launches ‘Operational Excellence Module’ (CTi-OEM) – a blockchain clinical trial application to tackle clinical trial inefficiencies and high costs. (ClinTex)

    The initial spark of an idea that would eventually become ClinTex started in 2014, at the DIA Forum in Vienna. By 2018, Clintex was formally working on the Clinical Trials Intelligence (CTi) platform. CTi’s purpose is to deliver data analysis at scale, to drive collaboration and insights across clinical trials.

    With large pharma companies like Merck and Novartis already testing blockchain as a technology of the future to support their clinical trial strategy for patient information and to manage clinical trial medication, this paves the way for ClinTex CTi to partner with the industry to deliver more innovative and impactful uses of blockchain to increase clinical trial efficiency.

    The CTi-OEM App
    Leveraging 50+ years of medicine development experience, ClinTex has moved at a breakneck pace to launch its first blockchain clinical trial app of the CTi Platform, the Operational Excellence Module (CTi-OEM). CTi-OEM provides intuitive operational oversight of clinical trials for clinical project managers, clinical data managers and remote staff; allowing in-stream decision-making on what actions are required to ensure a successful investigation into the safety and efficacy of new medicines.

    Using the CTi-OEM console, researchers can deep dive into clinical trial data and take proactive action to make clinical trials run more efficiently. These operational issues include things like clinical protocol deviations and adverse events relating to patient safety in the clinical trial.

    The company has prioritized the development of the CTi-OEM blockchain clinical trial app to target some of the major causes of inefficiency in clinical trials, enabling its first app to derive maximum tangible benefits for the pharma and clinical trials industry. CTi-OEM achieves this through a comprehensive portfolio of tools, which is accessible through the CTi-OEM console.

    Compliance Requirements & Patient Safety
    One of the major obstacles to a successful clinical trial is adherence to the clinical trial protocol. Analytics within the CTi-OEM application allows the detection and analysis of these deviations and allows the clinical trial team to take speedy action. These tools provide powerful insights into the major causes of non-compliance in clinical trials providing analytics to help clinical trial teams identify and resolve them to speed up progress.

    Protecting patient safety during a clinical trial is the most important aspect in the development of any new medicine. Adverse events are safety issues that occur during the testing of a new medicine. CTi-OEM provides valuable insight into patient safety throughout a clinical trial. For example, adverse event rate per site allows the clinical trial team to identify those sites that have a high rate of safety events which may point to procedural problems or may also uncover safety risks that need further investigation.

    These are just a few examples of CTi-OEM’s toolkit. For more information on CTi-OEM, there is a series of demonstration videos that give an overview of the platform, and how it can help alleviate pain points in clinical trials. Any clinical trial professionals interested in learning more or becoming early adopters can email ClinTex at industry@clintex.io or visit http://clinicaltrialsintelligence.org.

    CTi-OEM is just the beginning for ClinTex offerings. Eventually, the platform will consist of 7 different blockchain clinical trial applications that derive intelligent analytics from all types of clinical trial data, and it is these analytics that can be used to drive efficiency in clinical trials. The ClinTex roadmap is on track to have live client onboarding and revenue generation by the end of 2022.

    ClinTex Socials
    Twitter : https://twitter.com/ClinTexCTi
    Telegram : https://t.me/ClinTexCTi
    Medium : https://medium.com/clintexcti
    YouTube : https://youtu.be/iK3zkhsDzzA
    Website : https://clintex.io/

    Media Contact Details
    Contact Email: press@clintex.io

    About ClinTex
    ClinTex CTi (Clinical Trials Intelligence) is a solution provider to the pharmaceutical industry, a new type of software platform aimed at transforming the medicine development industry through the application of predictive analytics, machine learning, and the novel use of blockchain technology and smart contracts in clinical trials. Our mission is to bring down the cost of medicine and improve the speed to market of new medicines for the people who need them, through vastly reducing development costs for the global pharmaceutical industry.

  • Showa Denko Revises Forecast of Consolidated Performance and Records Extraordinary Loss

    TOKYO, Aug 3, 2021 – (JCN Newswire) – Showa Denko (SDK; TSE:4004) announces that it revises its forecast of consolidated business results for the first half of the year ending on December 31, 2021 and that for the full year ending on December 31, 2021, both of which were announced on July 8, 2021. SDK also announces that it will record extraordinary loss.

    1. Revision of forecast of consolidated business results for January 1 – June 30, 2021

    (1) Revised forecast of consolidated business results for January 1 – June 30, 2021

    Please see www.sdk.co.jp/assets/files/english/news/2021/20210803_sdknewsrelease_e.pdf

    (2) Reasons for the revision

    Net sales hovers around the level of the previous forecast. However, operating incomes of all segments except the Others segment are expected to increase. Especially in the Showa Denko Materials segment, operating income is expected to increase due to a continuously tight supply-demand situation regarding its semiconductor related business. Also in the Petrochemicals segment, operating income is expected to increase due to higher-than-expected product prices resulting from a rise in raw naphtha price. As a result, our ordinary income is expected to show almost as much increase as that in our operating income. However, net income attributable to owners of the parent is expected to show slight improvement because we expect an increase in the extraordinary loss of about 10 billion yen.

    Major factors of the expected extraordinary loss to be recorded are loss on sale of two businesses of the Aluminum segment, which was announced on January 28, 2021, amounting to about 2.5 billion yen and impairment loss in fixed assets of Showa Denko Materials segment’s mobility business amounting to 3.5 billion yen.

    2. Revision of forecast of consolidated business results for January 1 – December 31, 2021

    (1) Revised forecast of consolidated business results for January 1 – December 31, 2021

    Please see www.sdk.co.jp/assets/files/english/news/2021/20210803_sdknewsrelease_e.pdf

    (2) Reasons for the revision

    In the Petrochemicals segment, net sales are expected to increase due to higher-than-expected prices of major products including ethylene resulting from a rise in raw naphtha price. In the Inorganics segment, net sales are expected to increase due to an increase in the sales volume of graphite electrodes resulting from tight supply-demand situation. In the Showa Denko Materials segment, net sales are expected to increase due to tight supply-demand situation in the semiconductor related business which is expected to continue into the second half of this year.

    Operating incomes are expected to increase in all segments except the Others segment, centering on the first half of 2021. As a result, our ordinary income is expected to show almost as much increase as that in our operating income. However, net income attributable to owners of the parent is expected to decrease due to recording of extraordinary loss.

    3. Recording of extraordinary loss

    In the first half of this year, SDK will record a loss on sale of two businesses of the Aluminum segment, which was announced on January 28, 2021, amounting to about 2.5 billion yen and an impairment loss in fixed assets of Showa Denko Materials segment’s mobility business amounting to 3.5 billion yen. In addition, in the second half of this year (July 1 – December 31), SDK expects that the Showa Denko Materials Segment will record additional cost of improvement in its business structure amounting to about 15 billion yen.

    About Showa Denko K.K.

    Showa Denko K.K. (SDK; TSE:4004, ADR:SHWDY) is a major manufacturer of chemical products serving from heavy industry to computers and electronics. The Petrochemicals Sector provides cracker products such as ethylene and propylene, the Chemicals Sector provides industrial, high-performance and high-purity gases and chemicals for semicon and other industries, the Inorganics Sector provides ceramic products, such as alumina, abrasives, refractory/graphite electrodes and fine carbon products. The Aluminum Sector provides aluminum materials and high-value-added fabricated aluminum, the Electronics Sector provides HD media, compound semiconductors such as ultra high bright LEDs, and rare earth magnetic alloys, and the Advanced Battery Materials Department (ABM) provides lithium-ion battery components. For more information, please visit www.sdk.co.jp/english/.

    For further information, contact:
    Showa Denko K.K., IR Office, Finance & Accounting Department, Tel: 81-3-5470-3323

  • The GBA Annual Achievement Awards

    The GBA Annual Achievement Awards

    In April 2019, during the Guatemalan election, the people of Guatemala suspected that voting fraud had occurred. Since additional elections were scheduled for August 2019, citizens wanted assurance that there would be no fraud in the next election. That was the impetus for Fiscal Digital, a Guatemalan citizen volunteer organization, to utilize a public immutable blockchain for their elections. Against overwhelming opposition, the Organizer of Fiscal Digital, Carlos Toriello Herrerias, was successful in implementing a blockchain-based voting solution in Guatemala. Carlos was the winner of last year’s GBA Annual Achievement Award for Courage.

    The Government Blockchain Association (GBA) is pleased to announce that the 2021 Annual Achievement Awards will be happening live in Washington DC, (9/30/2021) as part of Government Blockchain Week. Four awards will be presented in the areas of Leadership, Innovation, Social Impact and Courage. Nominations of individuals deploying exceptional blockchain use will come from around the globe. From securing land titling records, to self-sovereign medical records, to immutable and verifiable voting, blockchain is affecting every industry that transfers value. The winners of these awards are truly making a mark in history, and there is still time to nominate your colleague.

    Winners will be awarded by MC Robert Levin of Emergingstar Capital, from a stage in Washington DC in front of a distinguished audience. Receiving a GBA Annual Achievement Award is a credential that can be listed on Linked In, resume, and any other social media as a recognized global achievement. Do not miss this opportunity to promote the exceptional achievers in your circle. Nominate them for the GBA Annual Achievement Awards today.

    Annual Achievement Awards (https://www.gbaglobal.org/gba-annual-achievement-awards-2021/) nominations are open until August 15. Winners will be announced from stage in Washington DC on September 30th. All uses of blockchain technology are eligible.

    #GBW2021 #GBAevents #GBAglobal

  • Straits receives approval from Marine Department to commence operation for Asia’s Largest STS Energy Transhipment Hub in Labuan

    Straits receives approval from Marine Department to commence operation for Asia’s Largest STS Energy Transhipment Hub in Labuan

    Straits Inter Logistics Berhad (Straits or Company), a Bursa Malaysia Listed Company, announced today that Victoria STS (Labuan) Sdn Bhd (Victoria STS) had received approval from Marine Department Malaysia on 30 July 2021 to commence operations to develop an integrated offshore Ship-to-Ship Transhipment Hub.

    The Company has mobilized its resources and infrastructure in preparation to commence operation of the STS Transhipment Hub in the coming fourth quarter 2021.

    Victoria STS is a 70% owned subsidiary of Fajar Maritime and Logistics Sdn Bhd, which in turn is a 60% owned subsidiary of Straits.

    Concurrently, Victoria STS has also on 30 July 2021 received approval from Marine Department Malaysia on the Marine Risk Assessment (“MRA”) in accordance with the terms of reference of MRA. The assessment was done as part of the requirements to be complied before 8 January 2022 to develop an integrated offshore Ship-to-Ship (“STS”) Energy Transhipment Hub within the port limits of Victoria Bay.

    The Company expects to commence and complete the development of the STS Energy Transhipment Hub which includes setting up the key facilities and equipment such as tugboats, pneumatic fenders, LNG cryogenic equipment and single point mooring system by the fourth quarter of 2021.

    Marine Department Malaysia had on 12 July 2021 granted the approval for the Company to develop the STS as announced to Bursa Malaysia.

    The STS hub will be Straits’ flagship energy project which will be located within the port limits of Victoria Bay deep water area spanning a vast 3309 hectares supporting an initial six (6) STS berths with safe water depths of up to 30 meters. The development will advance the introduction of state-of-the-art multi-functional energy transhipment facilities that will be able to accommodate LNG carriers up to the size of a Q-Max and Very Large Crude Carriers (VLCC).

    Victoria Bay is strategically located along international shipping and energy trade routes. Straits’ plan to develop the STS Hub is set to be one of the largest offshore LNG and LPG energy transhipment hubs in Asia. The STS hub is also strategically located within the vicinity of Labuan Liberty Port which is managed and operated by Megah Port Management Sdn Bhd (“MPM’), a 51% owned subsidiary of Straits.

    Commenting on the latest development, Straits Group Managing Director Dato Sri Ron Ho Kam Choy said, “Since our announcement on 12 July 2021 on the STS Transhipment Hub, we have received numerous enquiries from both notable international and local entities that are interested in partnering us to develop this into Asia’s largest STS Transhipment Hub. We are engaged in discussion with many parties in preparation for this project and Straits is gearing to kickstart this within the next few months. The other entities within the Straits Group will also stand to benefit from the business spin-offs of this project.”

  • SCCG Management and Data Sports Group Partner to Deliver Sports Content and Analytics to the Media Industry

    Stephen Crystal, Founder of SCCG Management, announced the completion of an agreement with Sowbhagya Shetty, CEO of Berlin, Germany based Data Sports Group (DSG), for a strategic consulting and business development in the US media markets.

    DSG provides highly accurate and consistent data for a wide number of traditional sports and esports events. Media publishers can unlock new commercial opportunities and revenue streams while readers get access to well-structured and compelling sports sections that bring editorial together with data & insights.

    Said Crystal on the announcement, “We are excited to be able to bring this powerful suite of content and analytics for traditional sports and esports to cable and television, mobile, web, and OTT media companies. The ability to deploy automated, AI-driven video with data and analytics is a powerful capability, which we can now easily deploy through DSG.”

    DSG provides highly accurate and consistent data for a wide number catalogue of sports and esports events. Media publishers can unlock new commercial opportunities and revenue streams while readers get access to well-structured and compelling sports sections that bring editorial together with data & insights.

    Sowbhagya commenting on the announcement, “DSG’s sports content is a perfect match for publishers, sports websites and betting affiliates. Media publishers looking to use sports betting content to monetize their userbase benefit by integrating our historical and live data across the full spectrum of professional sports.”

    DSG content suite in North America:
    – Sports Data & Statistics covering 40+ sports, 5000+ competitions including all US Sports
    – Odds feeds from leading bookmakers with prices for several markets
    – Sports News content, meta-tagged for searchable content structure
    – Data-driven sport videos
    – Create user-focused content & betting research tools using a vast sports content library

    About DSG

    Data Sports Group provides live sports data to media publishers and gaming segments with data feed services and rich front-end solutions.

    About SCCG Management

    SCCG Management is a consultancy that specializes in sports betting, iGaming, sports marketing, affiliate marketing, technology, intellectual property protection, product commercialization, esports, capital formation, M&A, joint ventures, casino management, and governmental and legal affairs for the casino and iGaming industry.

    Contact:
    Stephen Crystal
    SCCG Management
    +1 (702) 427-9354
    stephen.crystal@sccgmanagement.com
    Website: https://sccgmanagement.com

  • CEKD Berhad Signs IPO Underwriting Agreement with M&A Securities

    CEKD Berhad Signs IPO Underwriting Agreement with M&A Securities

    CEKD Berhad (CEKD or the Company), a die-cutting solutions provider as well as manufacturer of die-cutting moulds and trader of related consumables, tools and accessories, has on even date signed an underwriting agreement with M&A Securities Sdn Bhd (M&A Securities).

    This underwriting agreement is a precursor to the upcoming initial public offering (IPO) of the Company on the ACE Market of Bursa Malaysia Securities Berhad (Bursa Securities) that will take place in September 2021.

    L-R: M&A Securities Head of Corporate Finance Mr. Gary Ting; M&A Securities Managing Director of Corporate Finance Datuk Bill Tan; CEKD Managing Director Ms. Yap Kai Ning; CEKD Deputy Executive Chairman Mr. Yap Tian Tion

    As reported in the prospectus exposure on the Securities Commission’s website, CEKD’s IPO entails a proposed public issue of 50.59 million shares where 9.73 million shares will be made available for application by the Malaysian public. An additional 9.73 million will be allocated to eligible directors, employees, and contributors to the Company; another 6.81 million shares will be reserved for private placement to selected investors and 24.32 million shares will be reserved for private placement to Bumiputera investors approved by the Ministry of International Trade and Industry (MITI).

    Under the agreement, M&A Securities will underwrite 19.46 million of the total proposed issue of shares allocated to the Malaysian public or through pink forms. The balance of 31.13 million issue shares available for application by Bumiputera investors approved by MITI and selected investors will not be underwritten and will be placed out by the M&A Securities.

    Managing Director of CEKD Berhad, Ms. Yap Kai Ning said, “The signing of the underwriting agreement brings us closer towards our goal of taking CEKD public through an IPO. As one of the leading custom die-cutting solutions providers in Malaysia, we believe that this will be extremely beneficial for CEKD in strengthening and solidifying our position in the industry from an operational and financial standpoint.”

    Managing Director of Corporate Finance of M&A Securities, Datuk Bill Tan said, “We are honoured to have been a part of CEKD’s journey towards listing on the ACE Market of Bursa Securities. We want to extend our appreciation for having been appointed as CEKD’s Adviser, Sponsor, Sole Underwriter and Placement Agent of the IPO. The Company has come a long way since its inception, and we are proud to have been a part of this important milestone in its history. This IPO marks another impressive achievement for the Company, and we wish them all success and the best.”

    CEKD’s principal market is mainly from Malaysia which contributed 85.6% of the overall revenue in the financial year ended 31 August 2020. CEKD’s customers are mainly from the paper printing and packaging, electrical and electronics, automotive, plastic packaging, textile and leather industries.

  • TheCapitalNet appoints Privity FZ LLE to expand MENA footprint

    TheCapitalNet appoints Privity FZ LLE to expand MENA footprint

    TheCapitalNet (TCN), a SaaS company driving digital transformation in the Private Investment, Innovation, and Startup ecosystem globally, today announced that it has appointed Privity FZ LLE, an independent venture-focused advisory firm in the UAE, to bring the TheCapitalNet ecosystem to stakeholders across MENA, powered by Privity’s strong presence and understanding of the ecosystem and the region.

    The MENA region is well placed on the digital transformation curve, backed by a growing investment landscape (know more about the investment landscape of MENA on TheCapitalNet TV [https://tv.thecapitalnet.com/tv/559544556]). The partnership aims to bring efficiencies and intelligence to stakeholders in the ecosystem provided for by the suite of products offered by TheCapitalNet.

    Startups, Innovation, and Investment
    TheCapitalNet products are used globally by Venture Capital firms, Private Equity funds, Angel Investors and networks, and family offices (TheInvestorNet); Incubators and Accelerators (TheIncubatorPro); Startups and Aspiring Entrepreneurs (TheBizPlanner) in many countries across the world, helping users attain a high degree of deal and business efficiency, with strong collaboration, secure data management and business intelligence.

    “The customers TCN were seeking to target in the MENA region were precisely those that Privity interacts with, and after witnessing the power and potential of the different SaaS products and solutions, it became evident that Privity join forces with TCN to evangelize Dr Bhatia’s mission in the MENA region,” said Sleem Hasan, Founder and CEO of Privity FZ LLE.

    “We are excited to partner with Privity,” said Dr Rakesh Bhatia, Founder and CEO of TheCapitalNet. “This partnership brings us a step closer to establishing a foothold in the MENA market, and exploring the innumerable possibilities that are present, and further realizing our vision of digitally enabling the stakeholders in the ecosystem here.”

    “We have an ideal partner in Privity, a strong player with an exceptional understanding of the MENA market,” added Rakesh. Gain insights into the MENA innovation and investment ecosystem from Mr. Sleem Hasan on TheCapitalNet TV *.

    * TheCapitalNet TV Special: Understanding the MENA startup and innovation ecosystem with Mr. Sleem Hasan –
    https://tv.thecapitalnet.com/tv/580670728.

    About TheCapitalNet
    TheCapitalNet, with offices in Dallas TX, Silicon Valley, and Hyderabad, India, is an enterprise SaaS and knowledge media venture operating in the Private Investments, Innovation, and Startup ecosystem. TheCapitalNet products drive the digital transformation journey by enabling business processes and making them smarter and more intelligent, thus redefining business operations, decision making, and business outcomes.
    – TheBizPlanner (www.thebizplanner.com)
    An application for Founders/Entrepreneurs to plan their businesses and connect with the private investment and innovation ecosystem, used by 17,000+ startups across 70+ countries globally.
    – TheIncubatorPro (www.theincubatorpro.com)
    An end-to-end productivity suite for incubators, accelerators, and/or open/corporate innovation with 180+ incubators and accelerators spread across various countries globally.
    – TheInvestorNet (www.theinvestornet.com)
    An application for private investors including PE/VC/Angel Networks/Family offices/CVCs to manage the end-to-end business operations with over two dozen investments firms spread across various countries globally.
    – TheCapitalNet.TV (www.thecapitalnet.tv)
    A knowledge media that produces and shares global content focusing on TheCapitalNet ecosystem through knowledge sessions, news and trends, research reports, interviews and discussions with over 6 million impressions across 110+ countries.
    Visit https://www.TheCapitalNet.com, Email: contact@thecapitalnet.com

    About Privity
    Privity FZ LLE was founded in 2004, an independent venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them to develop and grow. Privity is agnostic to geography and industry vertical, focusing on the quality of the entrepreneur and the compelling value proposition of the idea. Privity draws upon its unique methodology ‘4i’ – Ideas, Intelligence, Invention, Innovation – to deliver insightful advisory and consulting services. The 4i methodology is a result of Privity’s vast and diverse experience gathered over the years, as well as the application of highly specialized domain expertise.
    Visit https://www.privitylle.com, Email: info@privitylle.com

  • Legend Capital invests in Series A funding round of BioMap, a biological computing platform

    BioMap, a biological computing platform enterprise, has recently completed the Series A funding round worth over a hundred million US dollars, which Legend Capital participated in. The funds will be used to for R&D and talent recruitment.

    BioMap is positioned as an innovative medicine R&D platform driven by biological computing engine. It was co-founded by Robin Li in November 2020 and he currently serves as the Chairman. Through advanced computing and biotechnology, BioMap draws maps on disease targets and drug design to realize the Global First-in-class original drugs. In the future, BioMap will also focus on the field of immune mechanism of tumors, autoimmune diseases and fibrotic diseases.

    Richard Li, the President of Legend Capital, said: “It is our second cooperation with Baidu this year after the investment in Baidu’s AI chip unit Kunlun in March. We hope to continue to maintain close cooperation with Baidu in the field of scientific and technological innovation in the future. We take a positive long-term view of the integration of IT and life science and technology. BioMap empowers life science with AI, and accelerates the R&D of new drugs and diagnostic products through the integration and innovation of AI technology and cutting-edge biotechnology. In the future, Legend Capital hopes to realise the full potential of the advantages of our enterprise ecosystem in the field of healthcare, and promote BioMap’s cooperation with leading companies in related fields, so as to provide intelligent computing platform support for the healthcare industry, give impetus to industrial upgrading and benefit more patients. ”

    Legend Capital has been focusing resources to research the deep integration of healthcare industry and technology. In recent years, it has continued to explore the field of medical AI. In addition to BioMap, Legend Capital has also invested in AI microbial pharmaceutical company Xbiome, AI innovative drug development platform StoneWise, AI medical image assisted diagnosis company Deepwise, Lunit, AI medical pathology diagnosis company Deep Informatics, gene big data company Genowis, AI medical chronic disease management system company Ayshealth Technology, etc.